{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:35:31Z","timestamp":1765355731513},"reference-count":78,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.3892\/or.2013.2574","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T06:56:21Z","timestamp":1372402581000},"page":"1473-1482","source":"Crossref","is-referenced-by-count":31,"title":["Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71"],"prefix":"10.3892","volume":"30","author":[{"given":"FEI","family":"ZHAO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAN","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PATRICILIA","family":"KUNDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XUEMEI","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QIU-LING","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAO","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,6,28]]},"reference":[{"key":"key20180107223225_b1-or-30-03-1473","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3928\/0191-3913-19990101-04","article-title":"Recent developments in the management of retinoblastoma","volume":"36","author":"Shields","year":"1999","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"key20180107223225_b2-or-30-03-1473","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/107327480401100506","article-title":"Diagnosis and management of retinoblastoma","volume":"11","author":"Shields","year":"2004","journal-title":"Cancer Control"},{"key":"key20180107223225_b3-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(11)61137-9","article-title":"Retinoblastoma","volume":"379","author":"Dimaras","year":"2012","journal-title":"Lancet"},{"key":"key20180107223225_b4-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bjo.2008.150292","article-title":"The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death","volume":"93","author":"Kivela","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key20180107223225_b5-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/bjo.2010.181396","article-title":"Retinoblastoma in the Beijing Tongren Hospital from 1957 to 2006: clinicopathological findings","volume":"95","author":"Bai","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"key20180107223225_b6-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjo.2010.191130","article-title":"Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China","volume":"95","author":"Zhao","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"key20180107223225_b7-or-30-03-1473","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0189-6725.48570","article-title":"Malignant tumours of childhood in Zaria","volume":"6","author":"Samaila","year":"2009","journal-title":"Afr J Paediatr Surg"},{"key":"key20180107223225_b8-or-30-03-1473","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.ejca.2006.06.003","article-title":"Retinoblastoma incidence and survival in European children (1978\u20131997). Report from the Automated Childhood Cancer Information System project","volume":"42","author":"MacCarthy","year":"2006","journal-title":"Eur J Cancer"},{"key":"key20180107223225_b9-or-30-03-1473","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2008.138750","article-title":"Incidence of retinoblastoma in the USA: 1975\u20132004","volume":"93","author":"Broaddus","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key20180107223225_b10-or-30-03-1473","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/adc.80.2.171","article-title":"Late diagnosis of retinoblastoma in a developing country","volume":"80","author":"Chantada","year":"1999","journal-title":"Arch Dis Child"},{"key":"key20180107223225_b11-or-30-03-1473","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0167-8140(85)80016-5","article-title":"Treatment of retinoblastoma by precision megavoltage radiation therapy","volume":"3","author":"Schipper","year":"1985","journal-title":"Radiother Oncol"},{"key":"key20180107223225_b12-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archopht.1996.01100140521001","article-title":"Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy","volume":"114","author":"Gallie","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"key20180107223225_b13-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archopht.1996.01100140539004","article-title":"Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma","volume":"114","author":"Kingston","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"key20180107223225_b14-or-30-03-1473","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1200\/JCO.2012.43.5677","article-title":"Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring","volume":"30","author":"Veal","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180107223225_b15-or-30-03-1473","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2003.09.103","article-title":"Treatment of intraocular retinoblastoma with vincristine and carboplatin","volume":"21","author":"Rodriguez-Galindo","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107223225_b16-or-30-03-1473","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/08880018.2012.700387","article-title":"The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide","volume":"29","author":"Varan","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"key20180107223225_b17-or-30-03-1473","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/mpo.10249","article-title":"Treatment of overt extraocular retinoblastoma","volume":"40","author":"Chantada","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"key20180107223225_b18-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.23002","article-title":"Clinical characteristics and treatment outcome of children with intraocular retinoblastoma: a report from a Chinese cooperative group","volume":"57","author":"Gao","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"key20180107223225_b19-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2011.39.4254","article-title":"A cautionary tale: dosing chemotherapy in infants with retinoblastoma","volume":"30","author":"Leahey","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180107223225_b20-or-30-03-1473","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ophtha.2011.06.036","article-title":"Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma","volume":"119","author":"Shields","year":"2012","journal-title":"Ophthalmology"},{"key":"key20180107223225_b21-or-30-03-1473","first-page":"2325","article-title":"Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein","volume":"57","author":"Chan","year":"1997","journal-title":"Cancer Res"},{"key":"key20180107223225_b22-or-30-03-1473","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archophthalmol.2011.5","article-title":"Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience","volume":"129","author":"Gobin","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"key20180107223225_b23-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","article-title":"Carboplatin-associated ototoxicity in children with retinoblastoma","volume":"30","author":"Qaddoumi","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180107223225_b24-or-30-03-1473","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archopht.126.6.862","article-title":"The adverse events of chemotherapy for retinoblastoma: What are they? Do we know?","volume":"126","author":"Rizzuti","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"key20180107223225_b25-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/bjo.2005.072033","article-title":"Systemic carboplatin for retinoblastoma: change in tumour size over time","volume":"89","author":"Abramson","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key20180107223225_b26-or-30-03-1473","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.ejca.2009.05.011","article-title":"Cancer mortality in long-term survivors of retinoblastoma","volume":"45","author":"Marees","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180107223225_b27-or-30-03-1473","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/jjco\/hyq201","article-title":"Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan","volume":"41","author":"Araki","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"key20180107223225_b28-or-30-03-1473","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pbc.23278","article-title":"Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma","volume":"59","author":"Turaka","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"key20180107223225_b29-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/nm.2471","article-title":"The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine","volume":"17","author":"Tu","year":"2011","journal-title":"Nat Med"},{"key":"key20180107223225_b30-or-30-03-1473","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0163-7258(01)00140-1","article-title":"Artemisinin and its derivatives: an important new class of antimalarial agents","volume":"90","author":"Balint","year":"2001","journal-title":"Pharmacol Ther"},{"key":"key20180107223225_b31-or-30-03-1473","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1039\/B816679J","article-title":"Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents","volume":"39","author":"Chaturvedi","year":"2010","journal-title":"Chem Soc Rev"},{"key":"key20180107223225_b32-or-30-03-1473","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1371\/journal.pone.0000693","article-title":"artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells","volume":"2","author":"Efferth","year":"2007","journal-title":"PLoS One"},{"key":"key20180107223225_b33-or-30-03-1473","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10637-012-9873-z","article-title":"Development of artemisinin compounds for cancer treatment","volume":"31","author":"Lai","year":"2013","journal-title":"Invest New Drugs"},{"key":"key20180107223225_b34-or-30-03-1473","first-page":"123","article-title":"Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines","volume":"33","author":"Gong","year":"2013","journal-title":"Anticancer Res"},{"key":"key20180107223225_b35-or-30-03-1473","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/IGC.0b013e31824a67c9","article-title":"Selective radiosensitization of human cervical cancer cells and normal cells by artemisinin through the abrogation of radiation-induced G2 block","volume":"22","author":"Gong","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"key20180107223225_b36-or-30-03-1473","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(09)70320-2","article-title":"Pharmacogenetics of antimalarial drugs: effect on metabolism and transport","volume":"9","author":"Kerb","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key20180107223225_b37-or-30-03-1473","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.freeradbiomed.2004.06.023","article-title":"Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron","volume":"37","author":"Efferth","year":"2004","journal-title":"Free Radic Biol Med"},{"key":"key20180107223225_b38-or-30-03-1473","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","article-title":"artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells","volume":"10","author":"Berdelle","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key20180107223225_b39-or-30-03-1473","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0960-894X(00)00578-3","article-title":"Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle","volume":"11","author":"Li","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107223225_b40-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/molecules15031705","article-title":"The molecular mechanism of action of artemisinin - the debate continues","volume":"15","author":"O\u2019Neill","year":"2010","journal-title":"Molecules"},{"key":"key20180107223225_b41-or-30-03-1473","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","article-title":"Two to tango: regulation of Mammalian iron metabolism","volume":"142","author":"Hentze","year":"2010","journal-title":"Cell"},{"key":"key20180107223225_b42-or-30-03-1473","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-010-0849-4","article-title":"Role of ferritin alterations in human breast cancer cells","volume":"126","author":"Shpyleva","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107223225_b43-or-30-03-1473","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bbagen.2008.04.003","article-title":"Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents","volume":"1790","author":"Richardson","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"key20180107223225_b44-or-30-03-1473","doi-asserted-by":"crossref","first-page":"247597","DOI":"10.1155\/2012\/247597","article-title":"Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug","volume":"2012","author":"Crespo-Ortiz","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"key20180107223225_b45-or-30-03-1473","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: a new generation of protein database search programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"key20180107223225_b46-or-30-03-1473","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0731-7085(00)00360-5","article-title":"A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate","volume":"24","author":"Green","year":"2000","journal-title":"J Pharm Biomed Anal"},{"key":"key20180107223225_b47-or-30-03-1473","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2009.11.028","article-title":"Design of a fixed-dose paediatric combination of artesunate and amodiaquine hydrochloride","volume":"387","author":"Okwelogu","year":"2010","journal-title":"Int J Pharm"},{"key":"key20180107223225_b48-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"key20180107223225_b49-or-30-03-1473","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/j.1349-7006.2010.01729.x","article-title":"Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer","volume":"101","author":"Shimokata","year":"2010","journal-title":"Cancer Sci"},{"key":"key20180107223225_b50-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/bjo.2004.047928","article-title":"Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma","volume":"88","author":"Krishnakumar","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key20180107223225_b51-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1167\/iovs.05-1321","article-title":"Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation","volume":"47","author":"Wilson","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20180107223225_b52-or-30-03-1473","first-page":"317","article-title":"Derivatives of arteannuin B with antileukemia activity","volume":"27","author":"Deng","year":"1992","journal-title":"Yao Xue Xue Bao"},{"key":"key20180107223225_b53-or-30-03-1473","first-page":"541","article-title":"Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro","volume":"13","author":"Sun","year":"1992","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"key20180107223225_b54-or-30-03-1473","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/np50096a007","article-title":"Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells","volume":"56","author":"Woerdenbag","year":"1993","journal-title":"J Nat Prod"},{"key":"key20180107223225_b55-or-30-03-1473","first-page":"186","article-title":"Study on antitumor effect of sodium artesunate","volume":"16","author":"Yang","year":"1997","journal-title":"Cancer"},{"key":"key20180107223225_b56-or-30-03-1473","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int J Oncol"},{"key":"key20180107223225_b57-or-30-03-1473","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10637-008-9188-2","article-title":"Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production","volume":"27","author":"Buommino","year":"2009","journal-title":"Invest New Drugs"},{"key":"key20180107223225_b58-or-30-03-1473","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CAD.0b013e328336f57b","article-title":"Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells","volume":"21","author":"Morrissey","year":"2010","journal-title":"Anticancer Drugs"},{"key":"key20180107223225_b59-or-30-03-1473","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-009-1095-5","article-title":"Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo","volume":"65","author":"Du","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107223225_b60-or-30-03-1473","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/mol.64.2.382","article-title":"Molecular modes of action of artesunate in tumor cell lines","volume":"64","author":"Efferth","year":"2003","journal-title":"Mol Pharmacol"},{"key":"key20180107223225_b61-or-30-03-1473","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2298\/AOO0204279S","article-title":"Case report of a laryngeal squamous cell carcinoma treated with artesunate","volume":"10","author":"Singh","year":"2002","journal-title":"Arch Oncol"},{"key":"key20180107223225_b62-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/0008-5472.CAN-10-3614","article-title":"Ironing out cancer","volume":"71","author":"Torti","year":"2011","journal-title":"Cancer Res"},{"key":"key20180107223225_b63-or-30-03-1473","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000163611","article-title":"Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines","volume":"59","author":"Shterman","year":"1991","journal-title":"Pathobiology"},{"key":"key20180107223225_b64-or-30-03-1473","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","article-title":"The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin Immunol"},{"key":"key20180107223225_b65-or-30-03-1473","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clim.2006.06.006","article-title":"The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin Immunol"},{"key":"key20180107223225_b66-or-30-03-1473","doi-asserted-by":"crossref","first-page":"e42703","DOI":"10.1371\/journal.pone.0042703","article-title":"Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1","volume":"7","author":"Ba","year":"2012","journal-title":"PLoS One"},{"key":"key20180107223225_b67-or-30-03-1473","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1039\/c2mb05437j","article-title":"Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells","volume":"8","author":"Eichhorn","year":"2012","journal-title":"Mol Biosyst"},{"key":"key20180107223225_b68-or-30-03-1473","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.intimp.2011.08.017","article-title":"Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2\/M phase","volume":"11","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"key20180107223225_b69-or-30-03-1473","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1074\/jbc.M610375200","article-title":"Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds","volume":"282","author":"Mercer","year":"2007","journal-title":"J Biol Chem"},{"key":"key20180107223225_b70-or-30-03-1473","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1074\/jbc.M110.144188","article-title":"The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials","volume":"286","author":"Mercer","year":"2011","journal-title":"J Biol Chem"},{"key":"key20180107223225_b71-or-30-03-1473","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0304-3835(94)03716-V","article-title":"Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin","volume":"91","author":"Lai","year":"1995","journal-title":"Cancer Lett"},{"key":"key20180107223225_b72-or-30-03-1473","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/14728222.9.5.995","article-title":"Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds","volume":"9","author":"Lai","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"key20180107223225_b73-or-30-03-1473","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijpharm.2007.09.003","article-title":"Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation","volume":"354","author":"Nakase","year":"2008","journal-title":"Int J Pharm"},{"key":"key20180107223225_b74-or-30-03-1473","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1040-8428(01)00213-X","article-title":"The iron metabolism of neoplastic cells: alterations that facilitate proliferation?","volume":"42","author":"Kwok","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107223225_b75-or-30-03-1473","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1074\/jbc.M110.210047","article-title":"Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production","volume":"286","author":"Hamacher-Brady","year":"2011","journal-title":"J Biol Chem"},{"key":"key20180107223225_b76-or-30-03-1473","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2008.07.004","article-title":"Artemisinins: their growing importance in medicine","volume":"29","author":"Krishna","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"key20180107223225_b77-or-30-03-1473","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1371\/journal.pone.0000798","article-title":"Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate","volume":"2","author":"Kelter","year":"2007","journal-title":"PLoS One"},{"key":"key20180107223225_b78-or-30-03-1473","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.bcp.2008.10.015","article-title":"Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent","volume":"77","author":"Hartwig","year":"2009","journal-title":"Biochem Pharmacol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2574\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T18:41:15Z","timestamp":1645900875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,28]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,6,28]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.3892\/or.2013.2574"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2574","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,28]]}}}